Pharmaceutical Executive
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Pharmaceutical Executive - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
2024 Pharm Exec Top 50 Companies
Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.
Global - PharmExec
Aug 13, 2024 · Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
A Promising Option: Exxua - PharmExec
Aug 16, 2024 · In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
About Us - PharmExec
Pharmaceutical Executive® provides insights and stories behind successful commercial strategies, research and development (R&D), market access and more, to its audience of pharmaceutical executives.
2023 Pharm Exec Top 50 Companies
Jun 10, 2023 · Movers and shakers. As mentioned, Pfizer and AbbVie captured the top two spots again in the Pharma 50—the latter, notably, expected to maintain its solid momentum, even with Humira’s patent expiration this year, thanks to reinforcements Skyrizi for psoriasis (up 75.7% in sales in 2022 to $5.2 billion) and JAK inhibitor Rinvoq (with seven approvals so far, including rheumatoid arthritis and ...
Pharm Exec's Top 50 Companies 2020
Jul 9, 2020 · Outside the top 10, noteworthy observations for the rest of the Pharma 50 field include Japan-based Astellas Pharma moving up four spots to 19th, the additions of four other Asian companies to our list (Meiji Holdings, Japan, 27th; Yunnan Baiyao Group, China, 37th; Shanghai Pharmaceuticals Holding, China, 48th; Aurobindo Pharma, India, 50th), and Regeneron Pharmaceuticals’ climb from 38th to ...
Pharm Exec's Top 50 Companies 2019
Jul 12, 2019 · Dealing and diversifying. The BMS-Celgene and Roche-Spark deals, along with Eli Lilly’s $8 billion acquisition of Loxo Oncology, may signal the start of a wave of M&A activity in the industry that will last into 2020, analysts say, as companies look to increase diversification into new areas and put more R&D resources into therapeutic niches with strong pricing power, such as rare diseases.
2022 Pharm Exec Top 50 Companies
Jun 9, 2022 · If 2020 was the “Year of COVID,” as we referred to it in our Pharm Exec 50 feature last year—reflecting on the pandemic’s scope and disruption on all facets of life—then 2021 was surely the year of COVID vaccines and treatments. And, through the prism of our latest rankings of the top 50 global biopharma players based on prescription drug sales, one that will go down in the annals of ...